Breast and prostate cancers are both hormone-dependent, at least in some stages of their progression. Hormonal manipulation represents an important therapeutic approach. Although most of breast and prostate cancers initially respond to hormone therapy, most tumors reinitiate to growth. Finally, hormone-resistant and metastatic breast and prostate cancers may develop. Thus, the challenge is the dissection of mechanisms by which steroid receptor signaling pathways continue to influence cell growth and invasiveness. Compelling evidence indicates that steroid hormones elicit non-genomic responses in extra-nuclear compartment of target cells. In this cellular location, steroid-coupled receptors rapidly recruit signaling effectors or scaffold proteins and activate multiple pathways leading to proliferation, survival, migration and invasiveness. The immediate challenge is the dissection of key events regulating the steroid response of target tissues to prevent progression and improve treatment of breast and prostate cancers.

An increasing number of exercise scientists are applying their skills collaboratively (with medics and physiotherapists) to clinical populations and investigating the effects of exercise in relation to wide-ranging clinical, pathophysiological and psycho-social outcomes. The book is aimed at final year Undergraduate and Master's level students of Exercise Science, who are interested in working with clinical populations such as cancer patients. Many university Sport and Exercise Science courses in the UK and USA now have modules which are focused on exercise for health, and cover aspects of exercise science which are appropriate for clinical populations. The book would also be a very valuable resource for Undergraduate and Postgraduate Physiotherapy courses and a very useful resource for students of Exercise Science and Physiotherapy, as well as practitioners working with cancer patients.There are an increasing amount of research opportunities for exercise scientists who are interested in working with clinical populations. Furthermore, a considerable amount of Government and Charity research funding is being targeted at active lifestyles and this is helping to generate a new culture of collaboration between exercise scientists and medics. Hence, it is highly likely that an increasing number of students from Sport and Exercise Science courses will pursue careers within the clinical realm in the future. Practicing exercise therapists, clinical exercise physiologists and physiotherapists would also find lots of useful up-to-date knowledge to support their evidence-based clinical practice. This book would also be of interest to informed readers who are themselves undergoing or recovering from cancer treatment.

Hedgehog-GLI Signaling in Human Disease represents the first compilation of up-to-date reviews by top-level scientists in this important field of research. The chapters cover a wide spectrum of related interests, from the molecular bases of morphogen function, to human genetics to cancer research. The aim of the book is to disseminate information on this exciting field, to allow students, scientists and the public in general to gain access current information from research leaders and to provide a book that encompasses different aspects of research showing the fusion of basic research in model systems and medicine. This is a timely primer on how a system of cell communication, Hedgehog-GLI signaling, plays a critical role in human disease and thus provides the background for the development of novel and rational therapies.

Despite tremendous recent advances in the treatment of most malignancies, there remain several critical questions for each cancer. This particularly true for the surgical management of solid-organ malignancies. Comparative effectiveness is a relatively new term which encompasses the age-old concepts of how best to treat cancer patients. Comparative effectiveness is defined as the direct comparison of healthcare interventions to determine which work best for which patients when considering the benefits and risks. The Institute of Medicine has defined comparative effectiveness research(CER) as the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care. CER is certainly best done with well-conducted randomized controlled trials. Unfortunately, clinical trials are not always feasible owing to the impracticality of conducting the trial, the considerable cost, and the time required to complete the trial. These challenges are even more pronounced with respect to surgical treatment. Thus alternative approaches may need to be considered in order to address pressing questions in the care of the oncology patient. These approaches may include well-conducted retrospective cohort studies from cancer registries and other data sources, decision and cost-effectiveness analyses, and other novel methodologies. This book lays out the current critical questions for each major malignancy and proposes approaches to gain answers to these pressing questions.

The various cell types have traditionally been recognized and classified according to their appearance in the light microscope following the process of fixing, processing, sectioning, and staining tissues that is known as histology. Classical histology has been augmented by
immunohistochemistry (the use of specific antibodies to stain particular molecular species "in situ"). Immunohistochemistry has allowed the identification of many more cell types than could be visualized by classical histology, particularly in the immune system and among the scattered hormone-secreting cells of the endocrine system.
This book discusses all aspects of immunohistochemistry and "in situ" hybridization technologies and the important role they play in reaching a cancer diagnosis. It provides step-by-step instructions on the methods of additional molecular technologies such as DNA microarrays, and microdissection, along with the benefits and limitations of each method. The topics of region-specific gene expression, its role in cancer development and the techniques that assist in the understanding of the molecular basis of disease are relevant and necessary in science today, ensuring a wide audience for this book.
* The only book available that translates molecular genetics into cancer diagnosis
* Provides the readers with tools necessary to perform and optimize sensitive, powerful techniques, including immunohistochemistry and fluorescence in situ hybridization, used in tumor diagnosis
* Written by experts in this field, the book provides theoretical considerations as well as practical approaches to carry out effectively these techniques
* Offers suggestions, tips, cautions, and guidelines to avoid artifacts and misdiagnosis
* Introduces new techniques to detect genes and proteins involved in the initiation and progression of cancer
* Covers the latest developments and a wide range of applications to the detection of antigens and single-copy DNA and RNA
* Written in a uniform format, each chapter includes Introduction, Materials required, step-by-step detailed Methods, Results, Discussion, and comprehensive up-to-date References

In this book, clinicians and basic scientists from USA, India, and other countries discuss the rationales and clinical experiences with targeted approaches to treat, prevent, or manage cancer. Cancer is a hyperproliferative disorder that is regulated by multiple genes and multiple cell signaling pathways. Genomics, proteomics, and metabolomics have revealed that dysregulation of dozens of genes and their products occur in any given cell type that ultimately leads to cancer. These discoveries are providing unprecedented opportunities to tackle cancer by multi-faceted approaches that target these underpinnings. This book emphasizes a multi-targeted approach to treating cancer, the focus of the 5th International Conference on Translational Cancer Research that was held in Vigyan Bhawan, Delhi (India) from Feb 6-9, 2014.

Accumulating evidence supports the role of defects in post-transcriptional gene regulation in the development of cancer. RNA and Cancer examines the recent advances in our understanding of post-transcriptional gene regulation, especially RNA processing and its role in cancer development and treatment. A particular focus is mRNA splicing, but other topics such as microRNAs, mRNA stability, the perinucleolar compartment, and oligonucleotide therapeutics are also covered in detail. All chapters have been written by internationally renowned experts. The book is intended for all with an interest in gene regulation and cancer biology, and especially for those not directly working on RNA biology, including clinicians and medical students. It is hoped that it will stimulate further innovative research collaborations between RNA biologists and cancer researchers to the benefit of patients.

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics, including Mdm2 - a regulator of cell growth and death; the systematic progression of human cancer; seizing of T-cells by human T-cell leukemia/lymphoma virus type II; host cell dependent expression of latent Epstein-Barr virus genomes; and gene expression profiling of renal cell carcinoma and its implications in diagnosis prognosis and therapeutics.
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics, including Mdm2 - a regulator of cell growth and death; the systematic progression of human cancer; seizing of T-cells by human T-cell leukemia/lymphoma virus type II; host cell dependent expression of latent Epstein-Barr virus genomes; and gene expression profiling of renal cell carcinoma and its implications in diagnosis prognosis and therapeutics.

The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.

* Discusses cancer cell biology in relation to Genome stability and Cell cycle regulation Unique assembly of experts in these fields who wrote a comprehensive and deep up-to-date overview Discusses models for the understanding of DNA damage-dependent signal transduction and regulation in human cells Since the establishment of the DNA structure researchers have been highly interested in the molecular basis of the inheritance of genes and of genetic disorders. Scientific investigations of the last two decades have shown that, in addition to oncogenic viruses and signalling pathways alterations, genomic instability is important in the development of cancer. This view is supported by the findings that aneuploidy, which results from chromosome instability, is one of the hallmarks of cancer cells. Chromosomal instability also underpins our fundamental principles of understanding tumourigenesis: It thought that cancer arises from the sequential acquisition of genetic alterations in specific genes. In this hypothesis, these rare genetic events represent rate-limiting bottlenecks' in the clonal evolution of a cancer, and pre-cancerous cells can evolve into neoplastic cells through the acquisition of somatic mutations. This book is written by international leading scientists in the field of genome stability. Chapters are devoted to genome stability and anti-cancer drug targets, histone modifications, chromatin factors, DNA repair, apoptosis and many other key areas of research. The chapters give insights into the newest development of the genome stability and human diseases and bring the current understanding of the mechanisms leading to chromosome instability and their potential for clinical impact to the reader.

Information gathered from cell-free systems, cell cultures, animal models, and human studies, together provide important insights to our understanding of hormonal cancer causation, development, and prevention; the primary objective of these Symposia. A special emphasis is placed on the two major endocrine-related cancers, that is, breast and prostate. The emerging fields of colon, lung, and pancreatic cancers in relation to hormones are examined.

Edward B. Lewis' science is the bridge linking experimental genetics as conducted in the first half of the 20th century, and the powerful molecular genetic approaches that revolutionized the field in its last quarter. His Nobel Prize winning studies founded the field of developmental genetics and laid the groundwork for our current understanding of the universal, evolutionarily conserved strategies controlling animal development. A lesser-known aspect of Lewis' canon is the pioneering studies he carried out on ionizing radiation and human cancer. In doing so, he was propelled into a public storm over nuclear weapons testing policy. For the first time Lewis' key publications in the fields of genetics, developmental biology, radiation and cancer are compiled within one volume. commentaries on the papers placing them in their scientific and historical context and, throughout, giving insight into Lewis' approach to science and the motivations that drove Lewis' choice of subject matter. This book will be invaluable to a wide audience of professionals in the life and biomedical sciences; including geneticists, developmental biologists, molecular biologists, radiation biologists and cancer researchers. It provides source material for advanced undergraduate and graduate level courses in genetics, developmental biology, radiation and cancer. In addition, historians of science will find it to be a valuable resource both because it contains original research publications and because of the illuminating commentary.

Cancer continues to be a growing problem as it is the foremost cause of death worldwide, killing millions of people each year. The number of people battling cancer continues to increase, owing to different reasons, such as lifestyle choices. Clinically, determining the cause of cancer is very challenging and often inaccurate. Incorporating efficient and accurate algorithms to detect cancer cases is becoming increasingly beneficial for scientists in computer science and healthcare, as well as a long-term benefit for doctors, patients, clinic practitioners, and more. Specifically, an automation of computation in machine learning could be a solution in the next generation of big data science technology. Machine Learning in Cancer Research With Applications in Colon Cancer and Big Data Analysis presents algorithms that have been developed to evaluate big data approaches and cancer research. The chapters include artificial intelligence and machine learning approaches, as well as case studies to solve the predictive issues in colon cancer research. This book includes concepts and techniques used to run tasks in an automated manner with the intent to improve better accuracy in comparison with previous studies and methods. This book also covers the processes of research design, development, and outcome analytics in this field. Doctors, IT consultants, IT specialists, medical software professionals, data scientists, researchers, computer scientists, healthcare practitioners, academicians, and students can benefit from this critical resource.

This handbook provides a useful guide for the day-to-day management of people with breast cancer. It covers the journey from diagnosis to post-treatment comprehensive care. It explains when and why different treatment modalities are used, what the complications of both the disease and treatments are and how to manage them. Although this book has been written for students and health personnel working in a general hospital, it will be useful for those in specialist breast units as well. Dr Jenny Edge is a surgeon and head of Breast and Endocrine Surgery at the University of Stellenbosch. Dr Ines Buccimazza is head of the Breast Unit, member of the Multidisciplinary Breast Team and a senior specialist in the Department of Surgery at the Nelson R. Mandela School of Medicine at the University of KwaZulu-Natal in Durban.

Primary Liver Cancer: Surveillance, Diagnosis and Treatment focuses on the many therapies rapidly evolving to assist with controlling hepatocellular carcinoma as well as emerging technologies to assist in early diagnosis as well as prevention. All chapters are written by experts in their fields and include the most up to date information for diagnosis, treatment, surveillance, epidemiology, staging, recurrence and prevention. This volume will serve as a useful resource for clinical gastroenterologists, hepatologists, oncologists, pathologists, and physicians who treat patients with chronic liver disease and hepatocellular carcinoma.

The book covers the complete field of testis cancer including the germ cell tumors and the stromal tumors, from epidemiology to new chemotherapeutic agents and schedules, throughout genetic features, risk factors, risk adapted treatments, role of different types of surgery and special clinical situations. Special attention is focused on fertility issues, late effects of the primary therapy and the economical aspects of the different treatment policies.

As a result of the third Consensus Conference, a consensual follow-up can be devised and a chapter dedicated to this controversial and not yet defined matter.

This book is the state-of-the-art reference text on testis cancer and is an essential resource for all urologists, medical oncologists and radio-oncologists.

With a particular emphasis on tumor dormancy in breast, lung, prostate, and liver cancers, as well as in melanoma, this first volume of a new Springer series focuses on the interrelationship between biological processes of aging and tumors -- both dormant and quiescent. With detail supplied by numerous international researchers at the forefront of cancer research, the book examines a host of differing aspects of the topic. Featured contributions analyze the role of the quiescent state in regulating hematopoietic and muscle stem cells. They also explore the mediation, by the kinase, in the reversible quiescent state of a subset of ovarian, pancreatic, and colon cancers. The book includes key research on the molecular mechanisms underlying stress-induced cellular senescence, in addition to those governing the accumulation of reactive oxygen species, and the induction of premature senescence. It also provides information on suppressing cellular senescence in the most common, and most aggressive malignant primary brain tumor in humans, glioblastoma multiforme. With comprehensive and cutting-edge information on therapeutic interventions and on the correct diagnosis of relevant neoplasms, and with numerous color illustrations, this is the most up-to-date assessment of current medical knowledge in this crucial area of medical research.

This book presents a comprehensive overview of current state-of-the-art clinical physiological imaging of brain tumors. It focuses on the clinical applications of various modalities as they relate to brain tumor imaging, including techniques such as blood oxygen level dependent functional magnetic resonance imaging, diffusion tensor imaging, magnetic source imaging/magnetoencephalography, magnetic resonance perfusion imaging, magnetic resonance spectroscopic imaging, amide proton transfer imaging, high angular resolution diffusion imaging, and molecular imaging. Featuring contributions from renowned experts in functional imaging, this book examines the diagnosis and characterization of brain tumors, details the application of functional imaging to treatment planning and monitoring of therapeutic intervention, and explores future directions in physiologic brain tumor imaging. Intended for neuro-oncologists, neurosurgeons, neuroradiologists, residents, and medical students, Functional Imaging of Brain Tumors is a unique resource that serves to advance patient care and research in this rapidly developing field.

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

This practical, compassionate, and inspiring book helps people with cancer navigate the often complex and difficult journey from diagnosis through treatment and life after disease. It illuminates the challenges associated with a cancer diagnosis and provides inspiration and guidance to help you not only to find the right doctors and care plan but also to cultivate hope and purpose. In Cancer with Hope, former CEO Mike Armstrong chronicles his experience with leukemia, prostate cancer, near-fatal sepsis, and a crippling autoimmune disease. Mike shares how his often difficult journey from humble beginnings to leading some of the world's top corporations taught him the importance of hope and purpose, tools that proved invaluable throughout his cancer journey. More than the tale of one man's experience with cancer, this important book includes expert advice and vetted resources to help patients best manage their disease, as well as compelling stories from a wide range of cancer patients who have faced seemingly insurmountable odds yet managed to maintain hope and find meaningful purpose.

A state-of-the art collection of readily reproducible laboratory methods for assessing chemosensitivity in vitro and in vivo, and for assessing the parameters that modulate chemosensitivity in individual tumors. Chemosensitivity, Volume 2: In Vivo Models, Imaging, and Molecular Regulators contains cutting-edge protocols for classifying tumors into response categories and for customizing therapy to individuals. These readily reproducible techniques allow measurements of DNA damage, apoptotic cell death, and the molecular and cellular regulators of cytotoxicity, as well as in vivo animal modeling of chemosensitivity. A companion volume, Volume 1: In Vitro Assays contains in vitro and in vivo techniques to identify which new agents or combination of agents are effective for each type of tumor

Lung cancer is the leading cause of cancer-related mortality. Metastatic lung cancer is responsible for more than ninety percent of lung cancer related deaths. However, relatively little progress has been made in understanding the process of lung cancer metastasis. The two main aims of this book are a) to introduce clinical aspects to basic scientists and basic molecular and cellular concepts to clinical investigators, in order to promote collaboration and foster much needed translational research; and b) to introduce new and emerging concepts and approaches in metastasis research to lung cancer research community at large. In this attempt, the book will cover a broad spectrum of subjects ranging from the current trends in the clinical management of the metastatic disease, to the systems biology approach for gaining insights into the mechanisms of metastasis. Some of the subjects covered will include: defining basic hallmarks of a metastatic cell, the concept of tumor stem cells, epithelial-mesenchymal transitions, evasion of immune-surveillance, tumor-stromal interactions, angiogenesis, molecular imaging and biomarker discovery.

Intraperitoneal Cancer Therapy investigates intraperitoneal chemotherapy in a variety of complex and interesting ways. The volume details major clinical trails to date, including immunotherapy, hyperthermic treatment of colo-rectal and ovarian cancers. Authors also examine regional approaches to therapy, systemic therapy, and the use of carboplatin and paclitaxel as the standard treatment for women with stages III and IV ovarian cancer. Other chapters also investigate techniques and procedures in treatment, as well as the future direction of both normothermic and hyperthermic intraperitoneal chemotherapy.

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics.
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics.

The detailed and comprehensive observations presented in this book on acquired cystic disease of the kidney and renal cell carcinoma in dialysis patients are drawn from the author 's decades of experience. Beginning with the first clinical case in 1978 and including subsequent follow-up studies and questionnaires, the volume is an excellent clinical reference for practicing physicians. Color illustrations and numerous case studies assist the reader.